Uncategorized - June 13, 2014
New discovery on the nervous system
The parasympathetic nervous system appears to be formed in a way that is different from what researchers previously believed, according to new research from the Karolinska Institute. The new study, published in the journal Science, alter a fundamental principal of our understanding of how the peripheral nervous system develops in the body. Researchers at Karolinska Institutet […]
Clinical Trials - June 13, 2014
Negative outcome in PMDD study
Umecrine’s drug candidate for PMDD treatment did not show any effect compared to placebo according to the results from a phase II study. In an exploratory double blind, randomized multicenter study, 120 patients with PMDD received, during one menstrual cycle, either placebo or one of two different doses of the drug candidate UC1010, a GABA-A […]
Agreement - June 13, 2014
AstraZeneca in lisence agreement for asthma project
The company has entered a global lisence agreement with Synairgen Plc, an AIM-listed UK company specialising in respiratory diseases. The agreement regards SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. AstraZeneca will pay Synairgen a $7.25 million up-front fee and potential development, regulatory and […]
Uncategorized - June 12, 2014
Italy to finance ESS
Italy will contribute with SEK 999 million to the construction of the European Spalliation Source in Lund. The amount is equivalent to six percent of the total cost which now is estimated to EUR 1.8 billion. Spain and France have previously announced that the two countries also will contribute. Sweden, Denmark and Norway will together […]
Financing - June 12, 2014
Targovax completes 70 MNOK financing
Immunotherapy specialist Targovax has completed a 70 MNOK financing, mainly from new investors. CEO Hanne M Kristensen states; “The capital increase of 70 MNOK will make us able to continue developing Targovax’s pipeline of immunotherapies targeting RAS mutated cancer forms, and also gives us a strong position to develop Targovax as a company”. Chairman Jónas Einarsson […]
Drug Development Pharma - June 12, 2014
Nordic Nanovector gets green light for Betalutin
The Norwegian company’s lead product candidate has been granted orphan designation in Europe. The European Medicines Agency (EMA) and the European Commission (EC) has now granted Betalutin orphan designation for treatment of follicular lymphoma in Europe. According to Nordic Nanovector, this will provide the company several advantages, The master travel anyone lisbon iowa singles stay […]
